Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body's natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. We show 16 historical shares outstanding datapoints in our GLUE shares outstanding history coverage, used to compute GLUE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GLUE market cap history over the course of time is important for investors
interested in comparing GLUE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GLUE versus a peer is one thing; comparing
GLUE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GLUE can fluctuate over the course of history.
With this page we aim to empower investors researching GLUE by allowing them to research the GLUE market cap history. |
Free GLUE Email Alerts:
Video: The Importance of Market Cap
